We quantitatively compare the efficacy of two approved EGFR tyrosine kinase inhibitors, erlotinib and gefitinib based on in vivo and in vitro data and show how a modeling approach can be used to scale from animal to humans.
Introduction
The success rate of developing anticancer drugs is reported to be around 5% in clinical development, which is considerably lower than in other therapeutic areas (1) . Model based drug development (MBDD) can increase the likelihood of compound development success (2) . It combines well designed in vitro and in vivo experiments with extensive data analysis and mathematical pharmacokinetic/pharmacodynamic (PKPD) modeling, providing a robust rational for comparing the chance of success of cancer drugs candidates. Thus the integration of experimental work and mathematical modeling is a valuable tool to improve effectiveness and reduce attrition rates during drug development (2) (3) (4) (5) . The model-based approach to predict the efficacious dose in humans based on animal data is useful to design early clinical trials which are mainly conducted in patients whose disease conditions are progressive and fatal. However, the optimal dose needs to be further refined as clinical data become available (6) .
Epidermal growth factor receptor (EGFR) is a widely explored target for cancer treatment as it plays a major role in tumor cell proliferation, regeneration, differentiation and development (7, 8) . Tyrosine kinase inhibitors (TKIs) are drugs blocking the phosphorylation and activation of the EGFR tyrosine kinase by binding to the ATP pocket of the kinase (9) . In this study, we compare two TKI, erlotinib and gefitinib (10) , based on their PKPD properties (11) .
Both compounds are orally administered to treat epidermoid cancers with high dependence on the EGFR pathway but without eliciting constitutive kinase or downstream activation (12) . They were both first approved for the treatment of non-small cell lung cancer (NSCLC) (13) (14) (15) and subsequently of various solid epidermoid cancers (16, 17) .
Erlotinib and gefitinib exhibit a similar mechanism of action (18) with different physicochemical properties (e.g., pKa) and different drug disposition characteristics (11, (18) (19) (20) . A thorough review of biology, pharmacokinetics and clinical aspects of erlotinib and gefitinib was recently reported by Bronte and colleagues (10) . In the mouse, rat, and human, gefitinib has a higher tumor tissue to plasma exposure ratio than erlotinib (21, 22) . In the present study we explore the relevance of high tumor-to-plasma ratio with regard to the pharmacologically active drug at the target site and its impact on efficacy. In vivo experiments were conducted in animal models of the human disease of interest, namely in in patient derived LXF A677 and cell-line derived VXF A431 tumor xenograft mice representing NSCLC and vulvar carcinoma respectively. With regards to B-raf mutational status, the cell line derived A431 is wild-type and the patient-derived A677 tumor is reported as BRAF D594A heterozygous. The effect of both drugs on a cellular level was explored in a cell cycle assay with A431 cells only since in vitro experiments were not feasible with the heterogeneous patient derived A677 tumor explant. pAkt and pErk, effector proteins for proliferation and survival downstream of the EGFR pathway, are upregulated in many cancer types with sustained EGFR signaling (23) (24) (25) (26) . Drug exposure in tumors and respective changes down-stream signaling represented by pERK levels were assessed. In addition, the long-term relationship between tumor size changes and exposure was characterized in a dynamic tumor growth inhibition (TGI) model.
In this study we combined experimentation with modeling and simulation to quantitatively compare the PKPD properties of erlotinib and gefitinib and explore how these findings translate to humans. We critically discuss the relevance of tumor to plasma ratio and how modeling and simulation can be applied to profile and select compounds in early drug discovery and development. The proposed approach illustrates how combining in vitro and in vivo experiments with a modeling approach provides insights into the dynamics of tumor growth as a function of drug dosage and the relevance of free drug concentration at the target site. The presented modelbased approach suggests a holistic way to profile drug candidates and is applicable to other anti-cancer drugs.
Material and Methods

In vitro cell cycle analysis
In vitro tests to monitor cell cycle arrest were conducted at Oncotest, Freiburg, Germany. A431 cells (ATCC® CRL-1555TM) were acquired from ATCC (Manassas, USA) in 2009 and have been tested and confirmed for authentication shortly after the experiments by short tandem repeat (STR) analysis at DSMZ, Braunschweig, Germany. A431 cells in subconfluent cultures were exposed to different concentrations (0.2 or 2 μM) of erlotinib or gefitinib at 37°C for 24, 48 or 72h. After washing, fixation with 70% ethanol/15% PBS/15% H 2 0 and staining with 10µg/ml RNAse A/10 µg/ml propidium iodide in PBS, cells were analyzed by flow cytometry on a FACS using Cytomics FC500 MPL (Beckman Coulter). The percentage of cells within defined cell cycle stages were calculated as a function of fluorescence intensity (Excitation 488 nm, Emission 585 nm/FL-2), using Cytomics™ RXP software as well as MultiCycle AV (Phoenix Flow Systems, USA).
In vivo xenograft mouse model
Female NMRI nu/nu mice were used for all in vivo studies and were supplied by Charles River (Sulzfeld, Germany).
Cell-line derived A431 and patient derived A677 tumor xenografts were grown subcutaneously (s.c.) in the mice by implantation of tumor fragments. Mice with tumor volume of 100-500mm 3 were randomized to different treatment groups and were sacrificed when tumor volume reached 2000mm 3 . At time of randomization the mice were between 7-11 weeks old with a body weight ranging from 18.2-34.3g. A short term PK/Target modulation (PK/TM) study to monitor TM after single and repeat dosing and a long term PK/Tumor growth inhibition (PK/TGI) to monitor tumor growth after repeat dosing were conducted. The treatment schedules of both studies are listed in Supplementary Table S1 . In general, both drugs and vehicle were administered daily per os (p.o.) at a volume of 5-20 ml/kg. All procedures were performed in accordance with the National Institutes of Health Guidelines for the In vivo PK/Biomarker -Target modulation (TM) study A short term PK/biomarker study was conducted to characterize the phosphor-and total Erk1/2 profile after treatment with erlotinib or gefitinib after single and repeat dosing in patient tumor A677 derived xenografts. Mice were treated daily with high dose erlotinib or gefitinib. Plasma PK, tumor PK and tumor pERK levels were collected at eight time points within 24 hours after singe and repeat dose. A detailed overview is given in the Supplementary Table S1 . Since pERK baseline levels of cell-line derived A431 were 4 fold lower as compared to A677 and too close to the quantification limit, changes in pERK upon treatment could not be quantified.
Tumor growth inhibition (TGI) study in xenograft mouse
A long term PK/TGI study was conducted to characterize tumor shrinkage after repeated oral drug administration.
The animals were randomized into seven groups (7 and 8 animals/group for A431 and A677 tumor xenografts respectively), with one vehicle group and three groups each for erlotinib and gefitinib with low, mid, and high dose. Plasma PK samples, one sample per mouse, were collected over 24 hours on Days 10 and 16 for A677 and on Day 3 for A431, as described in Supplementary Table S1 . Tumor size was successively measured via two dimensional caliper measurement, and tumor volume was calculated by ( × ) × 0.5, where "a" is the largest tumor diameter and "b" its perpendicular.
Biomarker (pERK) measurements
Native total protein lysates were prepared from patient derived A677 xenografted tumors upon terminal sampling.
Tumors were explanted and necrotic areas, large blood vessels and surrounding mouse tissue was removed.
Lysates from tumor samples were prepared under native conditions using lysate buffer containing protease and phosphatase inhibitors. Protein lysates were obtained from tumor tissues after homogenization and centrifugation. Supernatant was collected with a protein concentration of 5mg/mL. Aliquots were measured in an ELISA to determine pErk expression levels. The kit ELISA #DYC 1018 (R&D Systems GmbH, Germany) was used to 6 determine phosphor-Erk1/2 levels, and the assay was performed according to the manufacturer's instructions.
Lysates from two mice at one time point were pooled, and duplicates were measured. Absorbance was determined at 450nm (correction wavelength 570nm) using a plate reader (Perkin Elmer 1420 Multilabel Counter Victor3®).
PK analysis
PK measurements were conducted at Accelera, Milan, Italy using LC-MS/MS method. Blood and tumor samples were collected from xenograft mice during in vivo antitumor studies and plasma and tumor concentrations of erlotinib and gefitinib were measured. Tumor homogenates were prepared by ultrasonication. The lower limits of quantification (LLOQ) were 0.488 or 0.952ng/mL in plasma and 4.88 or 9.52ng/g in tumor tissue respectively. For erlotinib, the precision of the assay was 2.9-16.2% and 1.5-8.4% for the intra-day and inter-day variability, respectively. For gefitinib, the intra-day variability was 4.5 -18% % and 1.7 -6.2% for the inter-day variability. (AUC Tumor /AUC Plasma ) were computed for both tumor xenografts using short term PK data.
PK model structure
An oral, 1-compartment, model was fitted to the PK data from the short and the long term experiments.
The PK model can be described with the following equations: Where represents the quantity of drug in the depot compartment, the amount of drug in plasma, the plasma concentration and is the dose. , and correspond to the absorption and elimination constant rates and apparent volume of distribution, respectively. PK parameters estimates are later fixed in the PKPD models.
Target modulation PD model
A direct inhibitory effect model was used to fit the pErk profiles in A677 patient derived tumor xenografts after single dose using the corresponding PK data. A non-linear concentration-response relationship was assumed:
Where is the phosphorylated downstream biomarker in the tumor according to values, and is the baseline level of biomarker in absence of drug. and represent maximal inhibitory effect and total plasma concentration producing half of the maximum effect, respectively. is the unbound fraction of drug in plasma and is 0.055 or 0.06 for erlotinib or gefitinib, respectively (27) . , corresponding to the free plasma concentration producing half of the maximal effect, was derived by correcting for plasma protein binding in mice.
In order to have a metric for efficiency of the two drugs, the ratio was computed. AUCE is the area under the effect-time profile (pErk inhibition), and AUC Tu is the drug exposure in tumor tissue. AUC was calculated by non-compartmental analysis (NCA) in Phoenix WinNonlin 6.2 as described earlier, based on the data provided in 
Tumor growth inhibition model
Tumor volume (TV) was described by the sum of a growth-and killing function. A nonlinear growth model was fitted to the tumor growth data of the untreated mice. This model assumes a continuous switch from exponential to linear growth behavior as the tumor volume increases (28) . We estimated the drug effect via a killing function involving a direct and linear concentration effect model (29) . A schematic representation of the TGI PKPD model is given in Figure 2 and it is described with the following equation: 
Predicting human efficacious dose
We assume that free Css_stasis in plasma is a surrogate for free Css_stasis at the target site and that it is the same between mouse and human (denoted as Css_stasis free ), allowing us to convert this into a human efficacious dose by taking into account species differences in PK (e.g., plasma binding, clearances and volume of distribution) (20, 27).
The translation from the simulated total Css_stasis in plasma of mouse to a human daily dose was done as follows:
Css_stasis free is assumed to be the same in mouse and human and is derived by correction for the unbound fraction (fu) accounting for the species differences in plasma protein binding:
Where Css-stasis mouse is the simulated total plasma concentration in mouse at steady state to achieve tumor stasis, the unbound fraction in plasma, and Css-stasis human the total plasma concentration to achieve tumor stasis in human. The total plasma exposure in human required for tumor stasis, AUCss-stasis human , could then be derived:
Where is the dosing interval (i.e., 1 day in our case). Eventually a projected human daily dose, / , was derived by accounting for clearance in humans, : 
Parameter estimation
PKPD parameters were estimated using a population approach with Monolix Version 4.2.2. (Lixoft), allowing for estimation of fixed and random effects for each model parameter and a residual error in one step (31) . Residual errors for the PK were assumed to be proportional to predicted concentrations. For the PD, a combined error model was selected. Diagnostic plots were inspected to select the appropriate error model.
PK parameters were estimated separately from PD parameters to fix the individual PK input in the PKPD modeling.
PD parameters were estimated by combining erlotinib and gefitinib datasets while assuming similar tumor growth for both compounds, which allowed us to better differentiate efficacy from tumor growth parameters. In case of the target modulation experiment estimated random effects were the combination of inter and intra individual variability.
To allow a precise and stable estimation of fixed effects, random effects were fixed to low values if necessary. Model evaluation and selection was based on model convergence, precision of the parameter estimates, fitting criteria (Akaike Information Criteria (AIC)) and visual inspection of diagnostic tools (Visual Predictive checks, residuals and observed vs. predicted plots).
Results
Cell Cycle
The effects of both compounds on cell cycle arrest at a cellular level were explored in vitro. Cell cycle analysis was 
Tumor to plasma exposure ratio
After the in vitro assessment, the pharmacokinetic behavior of the two compounds was investigated in vivo on the basis of their total plasma and tumor exposure. Plasma and tumor PK time course profiles for both compounds and xenograft models are presented in Figure 1a -d. NCA was done to derive the AUC as readout of exposure in plasma and tumor for the two drugs. In both cell line derived A431 and patient derived A677 tumor models, gefitinib shows higher tumor to plasma exposure ratio as presented in Figure 1e . The ratio of tumor to plasma exposure (AUC Tumor /AUC Plasma ) was 21 times higher for gefitinib than erlotinib in the A677 xenograft model and 11-fold higher in the A431 tumor xenograft model.
Target modulation in tumor versus tumor and plasma concentrations
Next, we explored how the differences in the observed disposition properties compared to the down-stream effects in the tumor. Plasma and tumor PK and biomarker time course profiles were collected in a short-term, biomarker in vivo study. The observed data were used to relate the plasma and tumor exposure to the in vivo Total Erk levels in LXF A677 were constant at 1001±126 pg/mL over time in control and treatment groups (Supplementary Figure S4) . Measured pErk data in A677 after multiple dosing did not pass quality control due to unexplained fluctuations in the control group. Both drugs caused a rapid decrease in pErk levels (Figure 1f 
Modeling PK/TGI
After investigating the effects of erlotinib and gefitinib at a cellular and molecular level in vitro and in vivo, we compared the effects of the two compounds in vivo on tumor tissue. The time course of tumor growth in patient derived A677 and cell line derived A431 xenograft mice was monitored in a long-term experiment in TKI treated and untreated mice. A TGI model was fitted to the data in order to relate total plasma concentration to the in vivo TGI effect and quantify the effect of the respective drug. The diagnostic plots corresponding to the TGI PK modeling are shown in Supplementary Figure S5 . Prediction distribution and observed versus predicted plots for the A677 and A431 xenograft mice are presented in Figure 4 and Supplementary Figure S6 respectively. Overall, the model prediction describes the observed data well particularly in the low and mid dose group of both erlotinib and gefitinib. A bias is observed in the high dose group and the effect of erlotinib is under-predicted while the effect of gefitinib is over-predicted (Figure 4 ) or over-predicted for both drugs (Supplementary Figure S6) . Although this model misspecification in the high dose group, the model is still considered suited to address the main question on how higher tumor uptake translates to efficacy.
The PKPD parameters were precisely estimated with RSE values lower than 40%. High inter-individual variability was estimated on growth and efficacy parameters (>35% variability), which is also reflected in the wide 95% confidence interval around the predicted population profile in the diagnostic plots. The high inter-individual variability is precisely estimated and is indicative for the variability observed in the experimental data. This observation is most likely attributed to heterogeneous growth kinetics as a result of the xenograft tumor procedure which involved implanting of tumor fragments in the mice. The detailed parameter estimates are presented in Table 1 . In both tumor xenograft models, in vivo potency parameter estimates (k2) were about 3-fold higher for gefitinib than for erlotinib (Table 1 ). The secondary parameter Css_stasis, which represents the concentration at steady state needed to reach tumor stasis, was predicted to be 80-90 μg/L for erlotinib and 27-31 μg/L for gefitinib ( Table 2 ).
Translation of nonclinical efficacious concentration into a human efficacious dose
After characterizing the PKPD relationship in xenograft mice, we translated our results from mouse to human.
Css_stasis free values, human clearance and the predicted doses in human for both compounds and for both tumor types are presented in Table 2 . The projected doses by our modeling approach were ~140 and 120mg for Erlotinib and ~260 and 290mg for gefitinib for A677 and A431 respectively. The derived doses from the two xenograft models are very similar and they correspond well to the recommended standard therapeutic doses of 150 mg and 250 mg for erlotinib and gefitinib, respectively (10, 18) .
Discussion
The goal of this study was to differentiate erlotinib and gefitinib, both small molecular tyrosine kinase inhibitors of the human epidermal growth factor receptor (EGFR). The two compounds were selected based on the strong tumor uptake differences observed for erlotinib and gefitinib despite similar molecular specificity. The main purpose of the presented study was to better understand the impact of tumor uptake on in vivo efficacy. Gefitinib shows a higher tumor uptake in cancer patients and we explored the potential impact on pharmacological and anti-tumor activity in xenograft mice. We therefore combine experimentation with modeling to enable robust studies (21, 22) . Furthermore, despite the higher total exposure in tumors achieved with gefitinib, the effects on target modulation in tumors, monitored through pERK inhibition profiles, were similar for both drugs; the maximal effect on pErk inhibition was quickly achieved after administration of erlotinib and gefitinib. After the maximal effect was observed, the total concentration of gefitinib in tumor tissue further increased while pERK inhibition decreased. In contrast to erlotinib, the tumor PK profile of gefitinib did not follow the time course of pERK inhibition in tumor. These findings suggest that the high tumor-to-plasma ratio is not necessarily associated with a higher concentration of pharmacologically active drug at the target site and may be explained by a higher concentration bound to the tumor tissue. In summary, this short term biomarker experiment enabled to quantify target engagement as an indirect approach to estimate the free drug concentration at the site of action. Since this experiment requires terminal sampling, it was not feasible to include this in the long-term studies due to ethical constraints.
The higher tumor-to-plasma ratio observed with gefitinib can also be explained by the physicochemical properties of those drugs, especially the higher lipophilicity of gefitinib (10) . Furthermore, the tumor microenvironment becomes progressively hypoxic and the pH decreases when moving away from the blood supply in the tumor tissue (32, 33) . Erlotinib (pKa 5.4) and gefitinib (pKa= 5.4 & 7.2) are both weak bases (19) . Basic compounds ionize when pH is lower than their pKa value. Gefitinib will ionize faster in the acidic tumor microenvironment. Ionized compounds cannot cross membranes and might bind to negatively charged phospholipids of cell membranes (ionic trapping), decreasing the pharmacologically active fraction of drug in the tumor environment. This might explain why despite the higher total concentration of gefitinib than erlotinib at the target site, similar efficacy was observed for both compounds. The microenvironment at the target site is an important aspect in drug development that needs to be taken into account early on to distinguish two candidates on target accessibility as well as target concentrations.
PKPD modeling was conducted to quantitatively compare in vivo potency on biomarker and TGI response of two molecules with similar molecular specificity and distinct disposition characteristics. The direct linear effect PKPD model describes the data reasonably well despite the bias observed for the highest dose group. Various PKPD models (non-linear effect-, Emax model, additional cytostatic drug effect,…) were tested (data not shown) and did on October 28, 2017. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from not improve the model performance. It has been reported that resistance would occur under erlotinib or gefitinib treatment (13, 34) . Integration of time varying effect due to resistance in the model structure may improve the model performance. Genotyping of xenograft mice tumors to assess genetic alterations leading to TKI drug resistance (35) was not performed in this study.
Assuming passive exchanges from plasma to target site and an absence of active transporters, we considered free exposure in plasma to be a surrogate of free exposure at the target site when reaching steady state equilibrium (36) (37) (38) . Based on free concentration, gefitinib was around 5-fold more potent in target modulation and 3-fold more potent in TGI in mice. However, this 3-fold higher potency in tumor growth inhibition experiments is a best case scenario, given the fact that the tumor growth inhibition response of the high dose group was slightly overpredicted with gefitinib and under-predicted with erlotinib. However, the predicted human dose is in the same range as the human recommended doses for both compounds (10, 18) due to gefitinib's higher clearance in humans. It should be noted that the recommended standard therapeutic dose of gefitinib (250mg daily) is administered at approximately one third of its maximum-tolerated dose (MTD) (39) and is considered close to the biological dose. However, the recommended dose for Erlotinib (150mg daily) meets the classical definition of maximum-tolerated dose (40) . Therefore, the striking agreement between projected and recommended dose may be coincidental for erlotinib. PKPD models accounting for species-specific differences are valuable tools to profile and select compounds with a high probability of success (41) .
During nonclinical drug development, optimization of compound properties goes beyond the assessment of single drug metabolism and pharmacokinetic (DMPK) properties to consider the exposure-response relationship for both safety and efficacy. Knowledge about the active drug at the target site is crucial to optimize compound selection (41, 42) . Active drug at the target site is assumed to be the fraction of the compound available to bind to the target, the free fraction (43) . As seen in our comparison of erlotinib and gefitinib, for optimizing or comparing compounds, the total concentration exposure at the target site can be misleading because the free fraction at the site of action varies from compound to compound according to physicochemical properties and the target microenvironment.
Free drug concentration at tissue level is commonly measured by microdialysis (44, 45) . If the free fraction at the target site is not available, it might be predicted with compound properties or by generating appropriate in vivo In the present study we have shown how the combination of in vitro and in vivo experiments with mathematical modeling can be used to quantitatively characterize the PKPD properties of drugs and propose a way how these findings could be translated to humans. These projections are useful to select of most favorable dose in the early clinical trials. The FDA guideline for anticancer pharmaceuticals defines "the goal of selection a starting dose is to identify a dose that is expected to have pharmacological effects and is reasonably safe" (47) . Preclinical PK/PD modeling helps to project the pharmacological response in humans by quantifying the exposure response relationship in nonclinical species and subsequently accounting for the species differences. Moreover, profiling the therapeutic index in preclinical studies with subsequent prediction to humans is a critical step particularly owing to the narrow therapeutic index of most anticancer drugs. However, dose optimization needs to be further refined during the clinical trials. The comparative assessment done in this paper provides already valuable insights into the link between PK, tumor disposition in in vivo activity. Further studies including additional TKI inhibitors could be of value to further evaluate the impact of differences in molecular specificity on efficacy and to get mechanistic insights in what is driving the variability in patients' response. However, the main purpose of the proposed study was to better understand the impact of tumor uptake on in vivo efficacy and suggests a holistic view to profile compounds in preclinical studies. This proposed model-based approach is broadly applicable to other anti-cancer drugs. We demonstrated that total exposure at the target site is not sufficient to explain the pharmacological effect. Despite having a lower tumor to plasma ratio and a 3-5-fold lower in vivo potency compared to gefitinib, the prescribed daily dose of erlotinib in cancer patients is 50% lower. Our results suggest that the total exposure at target site may not be suited to rank compounds for efficacy, and an integrated modeling and experimental approach can assess efficacy more accurately. The presented model-based approach suggests how to leverage a broad range of experimental information using mathematical modeling in order to profile drug candidates and support dose finding for entry in human trials (EIH) in late stage patients and can potentially be applied and integrated in the drug discovery and development process of other anti-cancer drugs. Tables   Table 1 - 
Table 2 -Projected -and prescribed human doses
Comparison of simulated free concentration to achieve tumor stasis (Css_stasis free ) derived from xenograft mouse data and the resulting daily dose needed to reach tumor stasis in humans for gefitinib and erlotinib. The clearance and plasma protein binding values used in calculations for both species were retrieved from literature (20, 27). 
Simulations / Translations
